Cerevance’s First-In-Class Parkinson’s Candidate Shows Phase II Promise

CEO Predicts Annual Revenues Up To $1bn

Promising results from a small Phase II study will now propel the company’s CVN424 into pivotal trials, though its optimum dose is still unclear.

Parkinsons Drugs
The drug candidate could be used in combination with existing Parkinson's treatments, such as levadopa, but must first replicate the results in a larger pivotal study. • Source: Alamy

Cerevance has achieved Phase II trial success with its drug candidate reducing the time Parkinson’s disease patients spent in ‘Off time’ where symptoms recur despite medication.

CVN424 is the privately-held company’s lead candidate, and after producing encouraging safety, efficacy results and side-effect profile results, it now...

More from R&D

More from Scrip